Select Category

New Cure for Psoriatic Arthritis

Go Back

Posted on by

A new treatment for psoriatic arthritis was recently granted marketing approval by the European Commission.

Apremilast (brand name Otezla) is the new oral drug developed by Clegane UK, that can be used for the treatment of moderate-to-severe chronic plaque psoriasis in adults who have failed to respond to other systemic therapies including cyclosporine, methotrexate or psoralen and ultraviolet-A light. This new drug is also suitable for people who are intolerant to these treatment options. Apremilast can be used alone or in combination with disease modifying anti-rheumatic drugs (DMARDs) for the treatment of active psoriatic arthritis in adults who have proved unresponsive to previous DMARD therapy.

According to Dr Chris Edwards, a consultant rheumatologist at the University Hospital Southampton NHS Foundation Trust, “This decision marks an advance in the management of psoriasis and psoriatic arthritis… It fills a real gap in the therapies available for patients” and the fact it does not require regular monitoring is good news for both patients and doctors.

Facts from the trial

In a 16-week trial of apremilast, one third of patients receiving the treatment showed a significant improvement in psoriatic skin plaques – scaly, red, bumpy areas of skin that are often itchy. Benefits in itch, nail and scalp involvement were also noted, as well as an overall boost to quality of life.

When compared with the results of patients who received a placebo (dummy) treatment, twice as many people treated with apremilast experienced significant improvements to their condition. Benefits regarding the number of swollen joints, number of painful and tender joints, dactylitis, enthesitis and physical function were also experienced.

Now that marketing authorisation has been received, the treatment is to be assessed by both the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium, to see if it will be as clinically effective and cost effective as existing biological therapies.

#PsoriaticArthritis #Apremilast #BiologicalTherapy #Psoriasis #Arthritis

About Arthritis Center

This web site is run by an Arthritis Specialist based in Dubai, United Arab Emirates. On this site you will find news about the latest in arthritis, information about research results in the field, tips and information and diet and exercise, and much more.

More

Archives


Latest Blog

Using your genes to predict if you will respond to Rheumatoid arthritis therapy. (not available in Dubai, UAE at this time)

The ORBIT data “showed that patients who have seropositive rheumatoid arthritis are just as likely to respond to rituximab therapy when compared ...

Read More

Your nose can repair your knee arthritis? Not yet in Dubai!

Doctors might one day be able to harvest cells from patients’ noses to produce cartilage that can be transplanted into damaged knee joints, a sma...

Read More

Green tea to the rescue!

Green tea has always been hailed for its anti-inflammatory properties. But researchers at Washington State University (WSU) in Spokane have now ide...

Read More

This web site is run by an Arthritis Specialist based in Dubai, United Arab Emirates. On this site you will find news about the latest in arthritis, information about research results in the field, tips and information and diet and exercise, and much more.

More

Recent Comments